Merck

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merck and other ETFs, options, and stocks.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.

CEO

Robert M. Davis

CEORobert M. Davis

Employees

72,000

Employees72,000

Headquarters

Rahway, New Jersey

HeadquartersRahway, New Jersey

Founded

1891

Founded1891

Employees

72,000

Employees72,000

MRK Key Statistics

Market cap

277.28B

Market cap277.28B

Price-Earnings ratio

20.44

Price-Earnings ratio20.44

Dividend yield

2.79%

Dividend yield2.79%

Average volume

9.69M

Average volume9.69M

High today

$110.84

High today$110.84

Low today

$109.17

Low today$109.17

Open price

$110.69

Open price$110.69

Volume

6.01M

Volume6.01M

52 Week high

$134.63

52 Week high$134.63

52 Week low

$99.14

52 Week low$99.14

MRK News

Benzinga 15h

Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock'

Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' Benzinga and Yahoo Finance LLC may earn commission or revenue on some it...

Benzinga 2d

Merck's Mumps Vaccine Controversy: Class-Action Lawsuit Alleges Anticompetitive Behavior, Court Shields From Liability

In the late 1990s, the FDA expressed concerns regarding the diminishing potency of Merck & Co., Inc.’s MRK mumps vaccine as it neared its shelf life. To addres...

Benzinga 2d

Merck Touts Phase 3 Success For $20B Cancer Drug Keytruda In Untreated Head And Neck Cancer Patients

On Tuesday, Merck & Co Inc MRK announced that the Phase 3 KEYNOTE-689 trial of Keytruda (pembrolizumab), as a perioperative treatment for patients newly diagnos...

Analyst ratings

85%

of 27 ratings

Buy

85.2%

Hold

14.8%

Sell

More MRK News

TipRanks 3d

Bicara Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Bicara Therapeutics (BCAX) with an Overweight rating. The firm says Bicara is Bicara is developing ficerafusp alfa, a fi...

Seeking Alpha 3d

Merck posts late-stage trial win for Keytruda in head and neck cancer

Merck (NYSE:MRK) announced Tuesday that its Phase 3 KEYNOTE-689, designed to evaluate its anti-PD-1 therapy Keytruda as a perioperative regimen in certain patie...

Simply Wall St 7d

Should Weakness in Merck & Co., Inc.'s Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 13% over the past three months. However, stock pri...